M&A Deal Summary

Medexus Pharma Acquires Medac Pharma

On October 16, 2018, Medexus Pharma acquired life science company Medac Pharma from medac gmbh for 50M USD

Acquisition Highlights
  • This is Medexus Pharma’s 2nd transaction in the Life Science sector.
  • This is Medexus Pharma’s largest (disclosed) transaction.
  • This is Medexus Pharma’s 1st transaction in the United States.
  • This is Medexus Pharma’s 1st transaction in Illinois.

M&A Deal Summary
Date 2018-10-16
Target Medac Pharma
Sector Life Science
Buyer(s) Medexus Pharma
Sellers(s) medac gmbh
Deal Type Divestiture
Deal Value 50M USD

Target

Medac Pharma

Chicago, Illinois, United States
website
Medac Pharma, Inc. is a pharmaceutical company. Medac Pharma focused on the development and commercialization of treatments for autoimmune diseases and oncology. Medac Pharma, Inc. was founded in 2012 and is headquartered in Chicago, Illinois.

Search 193,711 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Medexus Pharma

Bolton, Ontario, Canada

website

Category Company
Sector Life Science
Employees100
Revenue 77M CAD (2022)
DESCRIPTION

Medexus Pharma is a pharmaceutical company dedicated to serving the needs of the pediatric community. Pediapharm’s product portfolio includes NYDA®, a breakthrough treatment for head lice; Relaxa™, an osmotic laxative used to treat constipation; EpiCeram®, a non-steroid emulsion for eczema; naproxen suspension, indicated to treat pain and inflammation due to various conditions, including Juvenile Idiopathic Arthritis; Rupall™, an innovative new allergy medication with a unique mode of action; Otixal™, the first and only antibiotic and steroid combination ear drop available in single, sterile, preservative-free and unit-dose packaging; and Cuvposa™, for chronic severe drooling, a condition affecting a significant proportion of cerebral palsy patients.

DEAL STATS #
Overall 2 of 3
Sector (Life Science) 2 of 3
Type (Divestiture) 1 of 2
State (Illinois) 1 of 2
Country (United States) 1 of 2
Year (2018) 2 of 2
Size (of disclosed) 1 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-10-16 Medexus

Bolton, Ontario, Canada

Medexus, Inc. is a pharmaceutical company, that offers value to patients and healthcare professionals by providing market leading prescription and over the counter brands, enhancing quality of life and a healthy lifestyle. Medexus, Inc. was founded in 2000 and is based in Bolton, Ontario.

Buy CA$23M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2020-02-28 IXINITY

Chicago, Illinois, United States

IXINITY is a medicine used to replace clotting factor (factor IX) that is missing in adults and children at least 12 years of age with hemophilia B. Hemophilia B is also called congenital factor IX deficiency. Hemophilia B is an inherited bleeding disorder that prevents clotting.

Buy $30M

Seller(S) 1

SELLER

medac gmbh

Wedel, Germany

website

Category Company
Founded 1970
Sector Life Science
DESCRIPTION

medac gmbh is a provider of pharmaceutical products. Medac specializes in therapeutic agents for the treatment of oncological, urological and autoimmune diseases and their related symptoms. medac gmbh was founded in 1970 and is based in Wedel, Germany.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (Illinois) 1 of 1
Country (United States) 1 of 1
Year (2018) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal